STOCK TITAN

Oncolytics Biotech, Inc. - ONCY STOCK NEWS

Welcome to our dedicated news page for Oncolytics Biotech (Ticker: ONCY), a resource for investors and traders seeking the latest updates and insights on Oncolytics Biotech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Oncolytics Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Oncolytics Biotech's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.34%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
conferences earnings
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
earnings
Oncolytics Biotech, Inc.

Nasdaq:ONCY

ONCY Rankings

ONCY Stock Data

78.11M
66.96M
1.14%
6.99%
1.4%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Canada
Calgary

About ONCY

oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics’ clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.